FMP
Genenta Science S.p.A.
GNTA
NASDAQ
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
2.89 USD
0.2227 (7.7%)
About
ceo
Mr. Pierluigi Paracchi
sector
Healthcare
industry
Biotechnology
website
https://www.genenta.com
exchange
NASDAQ
Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
CIK
0001838716
ISIN
US36870W1009
CUSIP
36870W100
Address
Via Olgettina No. 58
Phone
39 02 26 43 46 81
Country
IT
Employee
14
IPO Date
Dec 15, 2021
Key Executives
